What is the main business of Geny?

The main business activity of Geny focuses on research and experimental development on biotechnology.

When was the company founded?

The company was registered in the Polish National Court Register (KRS) on October 20, 2022.

Where is the headquarters located?

The headquarters is located at: ul. Jana Henryka Dąbrowskiego 77A, 60-529 Poznań.

Who is on the management board?

The management board consists of: Cezary Piotr Ziarkowski (Member of the Management Board).

What is the share capital?

The share capital of the company is PLN 600,000 (approx. $162,075).

What period do the latest financial data cover?

The latest available financial statement covers the period from January 1, 2023 to December 31, 2023.

What revenue was generated?

The company reported a revenue of $0 in 2023, which is an increase of 102.6% compared to 2022.

Is the company profitable?

No, the company recorded a net loss of $5,840 in 2023. For comparison, in 2022 the loss was $4,491, meaning the company increased its loss by 22.6%.

Which cost dominates operating expenses?

The largest operating cost category falls under external services. This category amounted to $3,433 in 2023, representing 59% of all operating expenses.

GENYS.A.

Research and experimental development on biotechnology

KRS: NIP: REGON:

Overview

Status

Suspended

Registry date

2022-10-20

Share capital

600,000.00 PLN

Registered address

ul. Jana Henryka Dąbrowskiego 77A, 60-529 Poznań, Poland

Website

genlife.pl

Financials

Revenue history

Filing timeliness

No financial statement for 2024 – the filing deadline has passed. 2 of 2 financial statements were filed late (the longest delay 45 days for 2023). All were audited by a statutory auditor.

2024not filed
202329/08/2024
202224/07/2023

Filed on timeDelayFiling deadline

Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.

Statistics

How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2023.

Industry · Research and experimental development on biotechnology376 / 386

Top 97%

Division · Scientific research and development1,898 / 1,953

Top 97%

Sector · Professional, scientific and technical activities38,700 / 39,211

Top 99%

Voivodeship · Wielkopolskie48,798 / 49,541

Top 99%

Country · Poland487,467 / 495,867

Top 98%

Results vs industry

Revenue

This companyUSD 0.19MedianUSD 55.66kAverageUSD 2.70m

Net profit

This companyUSD -5.84kMedianUSD -1.27kAverageUSD -92.16k

Operating costs

This companyUSD 5.83kMedianUSD 65.85kAverageUSD 2.66m

Assets

This companyUSD 136.16kMedianUSD 133.19kAverageUSD 3.03m

Industry

Authorized Representatives

Cezary Piotr Ziarkowski – Management Board Member

Manner of representation

Each member of the management board is authorised independently to make and sign declarations on behalf of the company.

Supervisory board

Andrzej Krzysztof Wiczewski – Supervisory Board Member

Jacek Marek Wojciechowicz – Supervisory Board Member

Marcin Maciej Muraszko – Supervisory Board Member

Beneficial owners

Person	Rights

Bank accounts

Was a VAT taxpayer from 2022-11-03 to 2026-09-29.

Reason for removal: Art. 96 ust. 9a pkt 1 (business activity suspended for at least 6 consecutive months)

Debt

No entries in the National Debtors Register (KRZ).

Public aid

No public aid cases recorded in the last 10 years.

Competitors

Name	Revenue	Website
GenxoneS.A.	$665,361.35	genxone.eu
Polbiotech Laboratoriumsp. z o.o.	$645,943.81	polbiotech.pl
Relvosp. z o.o.	$120,693.26	relvo.pl
Microblicsp. z o.o.	$122,383.50	microblic.pl
Xenstatssp. z o.o.	$66,774.27	xenstats.com
Fungotechsp. z o.o.	$187.68	fungo.tech
Innervisionsp. z o.o.	$4.54	innervision.pl
ImmunotronicsP.S.A.	$0.16	immunotronics.net
Dystrogen TherapeuticsS.A.	–	dystrogen.com
MIMO BiotechP.S.A.	–	mimobiotech.com

Change history

Date	Event
2026-02-01	Business suspended
2022-10-20	Entered in the register

FAQ

Last updated: 2026-04-02